Exodus Point Capital Management, LP Chinook Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $776,889 - $1.14 Million	-41,701 Reduced 24.44%	128,955 $3.38 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $178,216 - $237,859	10,178 Added 6.34%	170,656 $3.36 Million
Q2 2022 Aug 19, 2022	BUY	$12.59 - $18.8 $2.02 Million - $3.02 Million	160,478 New	160,478 $2.81 Million
Q2 2021 Aug 16, 2021	SELL	$13.6 - $18.98 $188,387 - $262,910	-13,852 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.17 - $19.11 $196,282 - $264,711	13,852 New	13,852 $215,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.